<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03558295</url>
  </required_header>
  <id_info>
    <org_study_id>CHAOS</org_study_id>
    <nct_id>NCT03558295</nct_id>
  </id_info>
  <brief_title>CHAOS Registry Study</brief_title>
  <acronym>CHAOS</acronym>
  <official_title>CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Città della Salute e della Scienza di Torino</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRODUCTION: About 6-8% of patients undergoing PCI have an indication for long-term oral
      anticoagulants (OACs) due to various conditions such as atrial fibrillation (AF), mechanical
      heart valves, or venous thromboembolism. The addition of single or double antiplatelet
      therapy to OACs therapy results in an increase in bleeding complications (1-4). The standard
      of care of management in this patients, indicated by 2017 ESC focused update on dual
      antiplatelet therapy in coronary artery disease (5), recommends the use of a triple therapy
      (Aspirin, clopidogrel and OAC) for 1-6 months (depending on the ischemic and hemorrhagic
      risk), then continue with double therapy only up to twelve month (Aspirin or clopidogrel and
      OAC) and after twelve months continue with the OAC only; the use of prasugrel or ticagrelor
      as part of triple therapy should be avoided (6). Only RELY study enrolled a small number of
      patients, less than one thousand, treated with dabigatran plus DAPT. Moreover, In the recent
      RCTs (WOEST(7), PIONEER AF-PCI study(8) and REDUAL-PCI(9)) only the double therapy (Aspirin
      or Clopidogrel/ticagrelor and DOAC) against triple therapy with warfarin was tested; and
      furthermore patients enrolled in RCTs represent only a small and not always representative
      sample of people treated in everyday clinical practice, who report a large burden of
      comorbidities and an older age. Randomized head to head comparison of warfarin and DOACs
      life-long (over 12 months from the PCI) have not been performed yet with clinical events as
      end points.

      AIMS: Aim of the present study is to describe the contemporary management of patients who
      underwent a PCI and have an indication to OAC for AF evaluating the different types of
      combination therapies used (triple therapy with warfarin or with DOAC, single anti-platelet
      therapy plus warfarin or DOAC) and their management in the first year after a PCI in a
      &quot;real-life&quot; setting. Secondary we would also evaluate the safety (in term of bleedings) and
      the efficacy (in term of ischemic and cardioembolic events) of the use of the different
      combination of single or double antiplatelet with OACs, in patients with coronary artery
      disease.

      MATERIALS AND METHODS: This is a retrospective, multicenter study including patients
      presenting with coronary artery disease (acute or stable setting) undergoing to PCI, in
      single or double antiplatelet therapy (aspirin, clopidogrel, ticagrelor, prasugrel, aspirin
      and clopidogrel, aspirin and ticagrelor, aspirin and prasugrel) with an indication to
      anticoagulant therapy (warfarin, dabigatran, rivaroxaban, edoxaban). The different groups
      will be compared with a propensity score analysis with matching.

      Primary (efficacy) end-points:

        -  A composite end points including death, myocardial infarction, stent thrombosis,
           revascularization stroke (MACE).

        -  A composite end points including death, myocardial infarction, stent thrombosis,
           revascularization, stroke and BARC [Bleedings according to the Bleeding Academic
           Research Consortium] 2,3,5 (7,8): all events mutually exclusive (NACE).

      Secondary end-points: Individual components of NACE; Cardiac death; Stroke; Target vessel
      revascularization (TVR) and non TVR and the number of the revascularization.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Primary (efficacy and safety) end-points:Net Adverse Clinical Event - NACE</measure>
    <time_frame>12 months</time_frame>
    <description>Primary (efficacy and safety) end-points:
- Net Adverse Clinical Event - NACE at 12 months of follow up (a composite end points including death, myocardial infarction, stent thrombosis, revascularization, stroke and BARC [Bleedings according to the Bleeding Academic Research Consortium] 2,3,5 (8,9): all events mutually exclusive); expressed as a rate of events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary (efficacy and safety) end-points:Major Adverse Cardiac Event - MACE at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Primary (efficacy and safety) end-points:
- Major Adverse Cardiac Event - MACE at 12 months of follow up (a composite end points including death, myocardial infarction (excluding periprocedural myocardial infarction), stent thrombosis, revascularization, stroke); expressed as a rate of events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>after 12 months</time_frame>
    <description>Expressed as a rate of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) and non TVR and the number of the revascularization.</measure>
    <time_frame>after 12 months</time_frame>
    <description>Expressed as a rate of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>after 12 months</time_frame>
    <description>Expressed as a rate of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>after 12 months</time_frame>
    <description>Expressed as a rate of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>after 12 months</time_frame>
    <description>Expressed as a rate of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent revascularization</measure>
    <time_frame>after 12 months</time_frame>
    <description>Expressed as a rate of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>after 12 months</time_frame>
    <description>Expressed as a rate of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding BARC [Bleedings according to the Bleeding Academic Research Consortium] 2,3,5 (8,9): all events mutually exclusive); expressed as a rate of events.</measure>
    <time_frame>after 12 months</time_frame>
    <description>According with BARC [Bleedings according to the Bleeding Academic Research Consortium] 2,3,5 (8,9): all events mutually exclusive); expressed as a rate of events.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Ischem Heart Disease</condition>
  <condition>Primary Coronay Intervention</condition>
  <condition>Oral Anticoagulants</condition>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Anticoagulant</intervention_name>
    <description>warfarin, dabigatran, rivaroxaban, edoxaban</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary artery disease (acute or stable setting) in single or double
        antiplatelet therapy (aspirin, clopidogrel, ticagrelor, prasugrel, aspirin and clopidogrel,
        aspirin and ticagrelor, aspirin and prasugrel) associated with oral anticoagulant
        (warfarin, dabigatran, rivaroxaban, edoxaban)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with final diagnosis of CAD (stable CAD or ACS) treated with oral
             anticoagulants and who undwerwent a coronary artery intervention

          -  Age ≥ 18 years

          -  Obtained informed consent

        Exclusion Criteria:

          -  Oral anticoagulation indication other than atrial fibrillation

          -  Patients who underwent revascularization with thrombolysis or with BPAC

          -  Patients in active treatment with anti-cancer therapy

          -  Patients with a non obstructive coronary artery disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabrizio D'Ascenzo, MD</last_name>
    <phone>+390116335570</phone>
    <email>fabrizio.dascenzo@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio D'Ascenzo, MD</last_name>
      <phone>+390116335570</phone>
      <email>fabrizio.dascenzo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fabrizio D'Ascenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mattia Peyracchia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, Madsen JK, Hansen PR, Køber L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009 Dec 12;374(9706):1967-74. doi: 10.1016/S0140-6736(09)61751-7.</citation>
    <PMID>20006130</PMID>
  </results_reference>
  <results_reference>
    <citation>Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrøm SZ, Poulsen HE, Køber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010 Sep 13;170(16):1433-41. doi: 10.1001/archinternmed.2010.271.</citation>
    <PMID>20837828</PMID>
  </results_reference>
  <results_reference>
    <citation>Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.</citation>
    <PMID>23271794</PMID>
  </results_reference>
  <results_reference>
    <citation>Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L; RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011 Nov;32(22):2781-9. doi: 10.1093/eurheartj/ehr113. Epub 2011 May 7.</citation>
    <PMID>21551462</PMID>
  </results_reference>
  <results_reference>
    <citation>Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2018 Jan 1;53(1):34-78. doi: 10.1093/ejcts/ezx334.</citation>
    <PMID>29045581</PMID>
  </results_reference>
  <results_reference>
    <citation>Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013 May 21;61(20):2060-6. doi: 10.1016/j.jacc.2013.02.036. Epub 2013 Mar 21.</citation>
    <PMID>23524219</PMID>
  </results_reference>
  <results_reference>
    <citation>Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.</citation>
    <PMID>19717844</PMID>
  </results_reference>
  <results_reference>
    <citation>Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van 't Hof AW, ten Berg JM; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013 Mar 30;381(9872):1107-15. doi: 10.1016/S0140-6736(12)62177-1. Epub 2013 Feb 13.</citation>
    <PMID>23415013</PMID>
  </results_reference>
  <results_reference>
    <citation>Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016 Dec 22;375(25):2423-2434. doi: 10.1056/NEJMoa1611594. Epub 2016 Nov 14.</citation>
    <PMID>27959713</PMID>
  </results_reference>
  <results_reference>
    <citation>Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27.</citation>
    <PMID>28844193</PMID>
  </results_reference>
  <results_reference>
    <citation>Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996 Dec;49(12):1373-9.</citation>
    <PMID>8970487</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>June 14, 2018</last_update_submitted>
  <last_update_submitted_qc>June 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Città della Salute e della Scienza di Torino</investigator_affiliation>
    <investigator_full_name>Fabrizio D'Ascenzo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Percutaneous coronary intervention (PCI), oral anticoagulants, atrial fibrillation, DOAC.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

